Abstract
Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL−1). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb
Trial registration:
ClinicalTrials.gov NCT02414854.
MeSH terms
-
Anti-Asthmatic Agents* / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Asthma* / drug therapy
-
Eosinophils
-
Humans
Substances
-
Anti-Asthmatic Agents
-
Antibodies, Monoclonal, Humanized
-
dupilumab
Associated data
-
ClinicalTrials.gov/NCT02414854